Severe Adverse Reaction to Vemurafenib in a Pregnant Woman with Metastatic Melanoma

Jorine de Haan, Johannes V van Thienen, Michael Casaer, Rebekka A Hannivoort, Kristel Van Calsteren, Minke van Tuyl, Mathilde M van Gerwen, Anne Debeer, Frédéric Amant, Rebecca C Painter, Jorine de Haan, Johannes V van Thienen, Michael Casaer, Rebekka A Hannivoort, Kristel Van Calsteren, Minke van Tuyl, Mathilde M van Gerwen, Anne Debeer, Frédéric Amant, Rebecca C Painter

Abstract

Targeted therapies have drastically changed the management of metastatic melanoma and have shown encouraging results on tumour progression but are also known for their high rates of adverse reactions. In general, targeted therapies are contraindicated during pregnancy due to concerns about teratogenesis. For the BRAF V600 inhibitor vemurafenib, the available literature about the effects on human pregnancy is limited to a single case report. In patients with metastatic melanoma that wish to continue their pregnancy, targeted therapies like vemurafenib offer the only possibility of improving maternal outcome. In this article, we report on a pregnant woman with metastatic melanoma who was treated with vemurafenib during pregnancy and experienced a fatal adverse reaction.

Keywords: Metastatic melanoma; Pregnancy; Toxic epidermal necrolysis; Vemurafenib.

Figures

Fig. 1
Fig. 1
Skin lesions 25 days after the start of vemurafenib.

References

    1. Sosman JA. Immunotherapy of advanced melanoma with immune checkpoint inhibition. UpToDate. 2015
    1. John L, Cowey CL. The Rapid Emergence of Novel Therapeutics in Advanced Malignant Melanoma. Dermatol Ther (Heidelb) 2015 Sep;5((3)):151–69.
    1. Lacouture ME, Duvic M, Hauschild A, Prieto VG, Robert C, Schadendorf D, et al. Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist. 2013;18((3)):314–22.
    1. McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3) extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014 Mar;15((3)):323–32.
    1. Grunewald S, Jank A. New systemic agents in dermatology with respect to fertility and lactation. J Dtsch Dermatol Ges. 2015 Apr;13((4)):277–89.
    1. Maleka A, Enblad G, Sjörs G, Lindqvist A, Ullenhag GJ. Treatment of metastatic malignant melanoma with vemurafenib during pregnancy. J Clin Oncol. 2013 Apr;31((11)):e192–3.
    1. Smith LH, Danielsen B, Allen ME, Cress R. Cancer associated with obstetric delivery results of linkage with the California cancer registry. Am J Obstet Gynecol. 2003 Oct;189((4)):1128–35.
    1. Van Calsteren K, Heyns L, De Smet F, Van Eycken L, Gziri MM, Van Gemert W, et al. Cancer during pregnancy an analysis of 215 patients emphasizing the obstetrical and the neonatal outcomes. J Clin Oncol. 2010 Feb;28((4)):683–9.
    1. Purdue MP, Freeman LE, Anderson WF, Tucker MA. Recent trends in incidence of cutaneous melanoma among US Caucasian young adults. J Invest Dermatol. 2008 Dec;128((12)):2905–8.
    1. Bleyer A, O'Leary M, Barr R, Ries LAG, editors. Cancer epidemiology in older adolescents and young adults 15 to 29 years of age including SEER incidence and survival 1975–2000. Bethesda: Natl Cancer Inst. 2006 NIH Pub. No.: 06-5767.
    1. Parazzini F, Franchi M, Tavani A, Negri E, Peccatori FA. Frequency of pregnancy related cancer a population based linkage study in Lombardy, Italy. Int J Gynecol Cancer. 2017 Mar;27((3)):613–9.
    1. Lee YY, Roberts CL, Dobbins T, Stavrou E, Black K, Morris J, et al. Incidence and outcomes of pregnancy-associated cancer in Australia,1994–2008 a population-based linkage study. BJOG. 2012 Dec;119((13)):1572–82.
    1. Amant F, Vandenbroucke T, Verheecke M, Fumagalli M, Halaska MJ, Boere I, et al. International Network on Cancer and Pregnancy (INCIP) Pediatric Outcome after Maternal Cancer Diagnosed during Pregnancy. N Engl J Med. 2015 Nov;373((19)):1824–34.
    1. Jeong H. Altered drug metabolism during pregnancy hormonal regulation of drug-metabolizing enzymes. Expert Opin Drug Metab Toxicol. 2010 Jun;6((6)):689–99.
    1. U.S. Food and Drug Association ZELBORAF (vemurafenib) tablet for oral use. 2017.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner